INO 5150

Drug Profile

INO 5150

Alternative Names: INO-5150

Latest Information Update: 23 Aug 2016

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 12 Jul 2016 Inovio Pharmaceuticals completes enrolment in its phase I trial for Prostate cancer in USA , (NCT02514213)
  • 27 Jul 2015 Phase-I clinical trials in Prostate cancer in USA (Parenteral)
  • 17 Nov 2014 Inovio Pharmaceuticals' DNA vaccines including INO 5150 are no longer licensed to Roche for the treatment of prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top